Prognostic significance of p53 mutations in colon cancer at the population level - PubMed (original) (raw)
. 2002 Jun 1;99(4):597-602.
doi: 10.1002/ijc.10405.
Affiliations
- PMID: 11992552
- DOI: 10.1002/ijc.10405
Prognostic significance of p53 mutations in colon cancer at the population level
Wade S Samowitz et al. Int J Cancer. 2002.
Abstract
Some studies have reported that p53 mutations or certain types of p53 mutation are associated with poor prognosis in colon cancer, while other studies have failed to show such a relationship. None of these previous studies was population-based. We therefore evaluated the prognostic significance of p53 mutations in a large, population-based study of 1,464 individuals with colon cancer from Utah and California. Mutations in exons 5-8 were detected by SSCP analysis, followed by sequencing of aberrant bands. p53 mutations were identified in colon cancers from 665 of 1,464 (45.4%) individuals. p53 mutations were significantly more common in distal tumors (p < 0.01), tumors of relatively high stage (p = 0.04), tumors without MSI (p < 0.01) and tumors without Ki-ras mutations (p < 0.01). In a univariate analysis, tumors with p53 mutations were associated with a significantly worse 5-year survival than those with wild-type p53 (53.4% vs. 58.8%, p = 0.04); significantly worse prognosis also was seen with missense mutations, transitions, transversions, mutations affecting the structure of the p53 molecule, mutations within the beta-sandwich motif and mutations in proximal tumors. In multivariate analyses, however, the only significant predictors of poor prognosis were G245 hot spot mutations (HRR = 2.16, 95% CI 1.06-4.40) and p53 mutations in proximal tumors (HRR = 1.34, 95% CI 1.07-1.63). We conclude that overall p53 mutational status is not an independent predictor of poor prognosis in colon cancer. However, specific classes of mutations, namely, the G245 hot spot mutation and mutations in proximal tumors, are related to significantly worse survival even after adjusting for age and stage.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
- Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer.
Catalano T, Curia MC, Aceto G, Verginelli F, Cascinu S, Cama A, Mariani-Costantini R, Teti D, Battista P. Catalano T, et al. Oncol Rep. 2005 Sep;14(3):625-31. Oncol Rep. 2005. PMID: 16077965 - Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL Jr. Ahnen DJ, et al. Cancer Res. 1998 Mar 15;58(6):1149-58. Cancer Res. 1998. PMID: 9515799 Clinical Trial. - Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study.
Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Samowitz WS, et al. Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1193-7. Cancer Epidemiol Biomarkers Prev. 2000. PMID: 11097226 - Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C, Taki T, Adachi M, Konishi T, Higashiyama M, Miyake M. Huang C, et al. Oncogene. 1998 May 14;16(19):2469-77. doi: 10.1038/sj.onc.1201776. Oncogene. 1998. PMID: 9627113 - Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, de Jong D, ter Elst A, Mulder NH, Buys CH, Hofstra RM, Plukker JT. Westra JL, et al. J Clin Oncol. 2005 Aug 20;23(24):5635-43. doi: 10.1200/JCO.2005.04.096. J Clin Oncol. 2005. PMID: 16110022 Clinical Trial.
Cited by
- DNA Methyltransferase 3A: A Significant Target for the Discovery of Inhibitors as Potent Anticancer Drugs.
Feng Q, Duan H, Zhou X, Wang Y, Zhang J, Zhang H, Chen G, Bao X. Feng Q, et al. Mini Rev Med Chem. 2024;24(5):507-520. doi: 10.2174/1389557523666230825100246. Mini Rev Med Chem. 2024. PMID: 37642180 Review. - Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium.
Heinzl N, Maritschnegg E, Koziel K, Schilhart-Wallisch C, Heinze G, Yang WL, Bast RC, Sehouli J, Braicu EI, Vergote I, Van Gorp T, Mahner S, Paspalj V, Grimm C, Obermayr E, Schuster E, Holzer B, Rousseau F, Schymkowitz J, Concin N, Zeillinger R. Heinzl N, et al. Oncogene. 2023 Aug;42(33):2473-2484. doi: 10.1038/s41388-023-02758-8. Epub 2023 Jul 4. Oncogene. 2023. PMID: 37402882 - Patterns of Somatic Variants in Colorectal Adenoma and Carcinoma Tissue and Matched Plasma Samples from the Hungarian Oncogenome Program.
Kalmár A, Galamb O, Szabó G, Pipek O, Medgyes-Horváth A, Barták BK, Nagy ZB, Szigeti KA, Zsigrai S, Csabai I, Igaz P, Molnár B, Takács I. Kalmár A, et al. Cancers (Basel). 2023 Jan 31;15(3):907. doi: 10.3390/cancers15030907. Cancers (Basel). 2023. PMID: 36765865 Free PMC article. - Association of β-Catenin, APC, SMAD3/4, Tp53, and Cyclin D1 Genes in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Yan H, Jiang F, Yang J. Yan H, et al. Genet Res (Camb). 2022 Aug 17;2022:5338956. doi: 10.1155/2022/5338956. eCollection 2022. Genet Res (Camb). 2022. PMID: 36072013 Free PMC article. - Cross-Talk between p53 and Wnt Signaling in Cancer.
Xiao Q, Werner J, Venkatachalam N, Boonekamp KE, Ebert MP, Zhan T. Xiao Q, et al. Biomolecules. 2022 Mar 15;12(3):453. doi: 10.3390/biom12030453. Biomolecules. 2022. PMID: 35327645 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
- CA 61757/CA/NCI NIH HHS/United States
- R01 CA061757-09/CA/NCI NIH HHS/United States
- N01-PC-67000/PC/NCI NIH HHS/United States
- CA 48998/CA/NCI NIH HHS/United States
- R01 CA061757/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous